Previous 10 | Next 10 |
Gainers: Diffusion Pharmaceuticals (DFFN) +36%, Strongbridge Biopharma (SBBP) +25%, KemPharm (KMPH) +20%, Senseonics Holdings (SENS) +17%, ReWalk Robotics (RWLK) +14%.Losers: bluebird bio (BLUE) -32%, Cortexyme (CRTX) -30%, Inhi...
Cortexyme (CRTX) tanks 24% premarket after receiving a letter from the FDA stating that a partial clinical hold has been placed on atuzaginstat (COR388) impacting the open-label extension ((OLE)) phase of the company’s Phase 2/3 study, the GAIN Trial (GingipAIN Inhibitor for ...
bluebird bio (BLUE) -30% after suspending sickle cell disease trial.Hepion Pharmaceuticals (HEPA) -28% after pricing stock offering.Cortexyme (CRTX) -26% after regulatory update on Atuzaginstat in Alzheimer’s Disease.Neptune Wellness Solutions (NEPT) -21%&...
- Double-blind phase of GAIN Trial to continue as planned, with top-line data expected Q4 2021 - Open-Label Extension of atuzaginstat to stop dosing and enrollment Cortexyme, Inc. (NASDAQ: CRTX), a clinical-stage biopharmaceutical company focused on Alzheimer’s and ot...
— Chris Lowe Promoted to Chief Operating Officer and Chief Financial Officer — Ted Monohon Promoted to Chief Accounting Officer —Drew Sukovich, Ph.D., RAC, Joins as Vice President, Regulatory and Quality Cortexyme, Inc. (Nasdaq: CRTX), a comp...
Gainers: [[NVAX]] +20.9%. [[SWKS]] +14.8%. [[WDC]] +10.2%. [[SCPS]] +8.9%. [[BBBY]] +8.5%.Losers: [[GSIT]] -20.8%. [[SNDE]] -17.9%. [[STIM]] -4.9%. [[FIZZ]] -4.2%. [[CRTX]] -3.7%. For further details see: NVAX, WDC, GSIT and FIZZ among after-hours movers
Cortexyme ([[CRTX]] +16.8%) says that based on interim analysis of GAIN Trial of its lead candidate atuzaginstat (COR388) in patients with mild-to-moderate Alzheimer's disease, the company announced pipeline expansion for 2021.Atuzaginstat will be evaluated in a new Phase ...
— Based upon successful completion of the GAIN Trial’s interim analysis, pipeline expansion announced for 2021 — Atuzaginstat to be studied in the PEAK trial, a new Phase 2 study for Parkinson’s disease — COR588, a novel lysine gingip...
CRTX thinks that a bacteria causes Alzheimer's, and it has research to back up that hypothesis. A Phase 3 trial will yield toppling data in Dec 2021, and they have enough cash. The risk-reward ratio is high for the molecule, but that's true for any Alzheimer's research. For ...
Cortexyme, Inc. (CRTX) is down -19.4% as Citi initiated coverage on the stock with a ‘Sell’ rating. Noting that risks from ‘company’s “unique” Alzheimer’s disease approach are still not reflected in the stock even after the recen...
News, Short Squeeze, Breakout and More Instantly...
New ticker symbol (Nasdaq: QNCX) to initiate trading on August 1, 2022 Cortexyme, Inc. (Nasdaq: CRTX) today announced that the company’s planned corporate name change to Quince Therapeutics is expected take effect on Monday, August 1, 2022. In conjunction with the cor...
Once daily dose of COR588 over 10-day period well-tolerated with no serious adverse events observed Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company focused on advancing therapeutics for rare and degenerative diseases, today reported the successful ...
Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company focused on advancing therapeutics for rare and degenerative diseases, today announced new preclinical data demonstrating the efficacy of the company’s 3CLpro inhibitor, COR803, for treatment of coronavirus...